StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Celgene (CELG) Remains In The Good Graces of Oppenheimer
October 27, 2017 11:09 AM
Oppenheimer maintains Outperform on Celgene (NASDAQ: CELG) price target of $163.00.Analyst Leah Rush Cann likes the highly ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Celgene (CELG) PT Lowered to $140 at Canaccord Genuity
October 27, 2017 11:05 AM
Celgene (CELG) Says Results from First Phase III Trial of Oral Ozanimod Versus an Active Comparator in Relapsing MS Presented at MSParis2017
October 27, 2017 9:06 AM
UPDATE: Morgan Stanley Upgrades Celgene (CELG) to Equalweight
October 27, 2017 5:57 AM
JMP Securities Downgrades Celgene (CELG) to Market Perform Citing Valuation
October 27, 2017 3:16 AM
Raymond James Double Downgrades Celgene (CELG) to Market Perform
October 26, 2017 3:57 PM
Wells Fargo Downgrades Celgene (CELG) to Market Perform, Cuts PT 'on Serial Disappointment'
October 26, 2017 10:52 AM
Celgene (CELG) Maintained Outperform at Oppenheimer, Defends Name
October 26, 2017 10:40 AM
